enow.com Web Search

  1. Ads

    related to: apixaban loading dose for dvt treatment reviews
  2. wexnermedical.osu.edu has been visited by 10K+ users in the past month

    262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464

Search results

  1. Results from the WOW.Com Content Network
  2. FDA Accepts Eliquis® (apixaban) Supplemental New Drug ... - AOL

    www.aol.com/2013/07/11/fda-accepts-eliquis...

    FDA Accepts Eliquis ® (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery PRINCETON, N.J. & NEW YORK ...

  3. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

    www.aol.com/news/2012-12-08-eliquis-apixaban...

    AMPLIFY-EXT (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment), a randomized, double-blind, multicenter trial ...

  4. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    In the EU, apixaban is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis (DVT) and ...

  5. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]

  6. Direct thrombin inhibitor - Wikipedia

    en.wikipedia.org/wiki/Direct_thrombin_inhibitor

    Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation. [1] Development was stopped by manufacturer AstraZeneca , however, because of reports of liver enzyme derangements and liver failure .

  7. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

    www.aol.com/news/2012-10-01-eliquis-apixaban...

    ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...

  1. Ads

    related to: apixaban loading dose for dvt treatment reviews